SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 8.55 |
| Enterprise Value ($M) | -2.98 |
| Book Value ($M) | 4.21 |
| Book Value / Share | 0.78 |
| Price / Book | 2.03 |
| NCAV ($M) | -14.40 |
| NCAV / Share | -2.68 |
| Price / NCAV | -0.59 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.49 |
| Return on Assets (ROA) | -0.10 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.97 |
| Current Ratio | 0.97 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 16.77 |
| Assets | 35.38 |
| Liabilities | 31.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 57.31 |
| Operating Income | -10.47 |
| Net Income | -8.12 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -41.82 |
| Cash from Investing | 29.09 |
| Cash from Financing | -9.12 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Sante Health Ventures I Lp | 10.10 | -90.61 | |
| 13G/A | Lytton Laurence W | 4.30 | ||
| 13G | Silverarc Capital Management, Llc | 6.60 | ||
| 13G/A | K2 HealthVentures Equity Trust LLC | 9.98 | ||
| 13G/A | Biotechnology Value Fund L P | 9.99 | ||
| 13G/A | Bb Biotech Ag | 19.20 | ||
| 13D/A | Longitude Capital Partners III, LLC | 5.70 | -93.33 | |
| 13G | Adage Capital Partners Gp, L.l.c. | 5.45 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 12,384 | 68,442 | 18.09 | |
| 14,261 | 16,036 | 88.93 | |
| 2,487 | 6,997 | 35.54 | |
| 8,962 | 5,871 | 152.65 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MLTX – MoonLake Immunotherapeutics | MNPR – Monopar Therapeutics Inc. |
| MRKR – Marker Therapeutics, Inc. | MYMD – MyMD Pharmaceuticals, Inc. |
| MYNZ – Mainz Biomed N.V. |
Financial data and stock pages provided by
Fintel.io